Boditech Med, Inc.
KKRX:2066408,580.00
KRW
+80.00
(+0.94%)
ISIN
KR7206640005
Return %
Stock
S&P 500
1Y
-38.45
14.39
3Y
-49.80
81.42
5Y
-48.47
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Ui-Yeol Choe
- Full Time Employees
- 601
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 43, Geodudanji 1-gil Chuncheon-si GA South Korea 24398
- IPO Date
- Dec 29, 2014
- Website
- boditech.co.kr
- Similar Companies
- Business
- Boditech Med Inc. specializes in the development and global distribution of advanced in-vitro diagnostic products and reagents. The company offers a suite of diagnostic platforms, including its ichroma™ series, such as ichroma™ II, ichroma™ III, ichroma™-50 plus, and the portable ichroma™ M2, which are fluorescence immunoassay analyzers designed for quantitative or semi-quantitative measurement of target analytes in bodily fluids like blood and urine. Its AFIAS line, featuring AFIAS-1, AFIAS-3, AFIAS-6, and AFIAS-10, provides automated immunoassay systems, some with all-in-one cartridge designs for streamlined testing. Complementing these systems, Boditech Med provides specialized devices like Hemochroma PLUS for total hemoglobin analysis, the ichroma™ TRIAS Reader for various sample types, and real-time PCR platforms such as ExAmplar and the automated nucleic acid extraction system NuActor. The company's extensive portfolio of over 90 biomarker test kits addresses a wide array of medical conditions, including cardiac health (e.g., ST2, NT-proBNP), various cancers (e.g., AFP, PSA, CA125), diabetes (e.g., HbA1c), hormonal imbalances, numerous infectious diseases (e.g., COVID-19, latent tuberculosis, sepsis), gastrointestinal disorders, rheumatoid arthritis, autoimmune conditions, and assessments for organ function, vitamin levels, and anemia. Recent innovations also include new veterinary diagnostic solutions like AFIAS-VET, VETCHROMA 3, UROCHROMA, and VETCHEMIS. Founded in 1998 and headquartered in Chuncheon, South Korea, Boditech Med has established itself as a leader in point-of-care testing (POCT), delivering rapid and reliable diagnostic solutions. The company's global footprint spans over 120 countries, supported by a network of sales agencies, with recent strategic expansions targeting manufacturing in India and increased market penetration in the Americas. In Q3 2025, Boditech Med reported solid financial results driven by growth in non-infectious disease product lines and emerging markets, alongside a significant increase in diagnostic device installations. It continues to innovate, recently signing an MOU for a global asthma diagnostic kit and unveiling advanced infectious disease and cardiovascular diagnostic platforms at major industry events. The firm is also advancing a smart production system that integrates digital and IT technologies, aiming to expand into new diagnostic areas such as clinical chemistry, chemiluminescence, CBC, and urinalysis.